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Abstract
Background: Drug-eluting stents (DES) reduce rates of restenosis compared with bare metal stents (BMS). A
number of observational studies have also found lower rates of mortality and non-fatal myocardial infarction with
DES compared with BMS, findings not observed in randomized clinical trials. In order to explore reasons for this
discrepancy, we compared outcomes after percutaneous coronary intervention (PCI) with DES or BMS by multiple
statistical methods.
Methods: We compared short-term rates of all-cause mortality and myocardial infarction for patients undergoing
PCI with DES or BMS using propensity-score adjustment, propensity-score matching, and a stent-era comparison in
a large, integrated health system between 1998 and 2007. For the propensity-score adjustment and stent era
comparisons, we used multivariable logistic regression to assess the association of stent type with outcomes. We
used McNemar’s Chi-square test to compare outcomes for propensity-score matching.
Results: Between 1998 and 2007, 35,438 PCIs with stenting were performed among health plan members (53.9%
DES and 46.1% BMS). After propensity-score adjustment, DES was associated with significantly lower rates of death
at 30 days (OR 0.49, 95% CI 0.39 - 0.63, P < 0.001) and one year (OR 0.58, 95% CI 0.49 - 0.68, P < 0.001), and a
lower rate of myocardial infarction at one year (OR 0.72, 95% CI 0.59 - 0.87, P < 0.001). Thirty day and one year
mortality were also lower with DES after propensity-score matching. However, a stent era comparison, which
eliminates potential confounding by indication, showed no difference in death or myocardial infarction for DES
and BMS, similar to results from randomized trials.
Conclusions: Although propensity-score methods suggested a mortality benefit with DES, consistent with prior
observational studies, a stent era comparison failed to support this conclusion. Unobserved factors influencing
stent selection in observational studies likely account for the observed mortality benefit of DES not seen in
randomized clinical trials.
Background
The comparison of alternative treatments has long been
a primary mission of both randomized trials and obser-
vational studies. With the commitment of $1.1 billion in
support of comparative effectiveness research in the
American Recovery and Reinvestment Act of 2009, the
number of studies comparing different drugs, devices,
techniques and systems will undoubtedly increase dra-
matically [1]. While randomized clinical trials are likely
to remain the gold standard for comparing alternative
treatments, observational studies should continue to
have significant, if not leading, roles in comparative
effectiveness research moving forward, particularly in
light of recommendations to prioritize assessments of
community-based interventions within populations tra-
ditionally underrepresented in clinical trials [2].
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ber of limitations, foremost among them the potential
for unmeasured variables that confound results. While a
number of methods directed at assessing causal effects
and eliminating confounding have been developed, few
clinical studies describe reasons for the specific choice
of method used, and fewer present multiple methods to
help corroborate findings[3,4].
Observational studies comparing drug-eluting stents
(DES) and bare metal stents (BMS) for percutaneous
coronary intervention (PCI) have consistently shown
lower mortality and myocardial infarction associated
with DES [5-20], findings not seen in randomized clini-
cal trials [21-27]. We applied three common methods to
compare DES to BMS within a large observational study
population to: 1) determine whether mortality benefit
for DES was observed in our study population and 2) to
identify potential challenges to the application of these
methods to compare treatments in the presence of
strong treatment selection.
Methods
We conducted a retrospective dynamic cohort study
within Kaiser Permanente of Northern California
(KPNC), a large integrated healthcare delivery system
caring for > 3.2 million individuals that are broadly
representative of the local surrounding and statewide
population[28]. All health plan members aged 30 years
and older between January 1998 and the end of Decem-
ber 2007 were considered eligible. The study was
reviewed by the institutional review board of the Kaiser
Division of Research, and requirement for informed
consent was waived due to the nature of the study.
From this cohort, we identified all PCI procedures using
either DES or BMS based on relevant International
Classification of Diseases, Ninth Revision, Clinical Modi-
fication (ICD-9-CM) and Current Procedural Terminol-
ogy (CPT) codes that occurred within health plan and
non-health plan hospitals [29]. Consecutive procedures
occurring within 7 days of one another were considered
part of the same clinical episode. Procedures in which
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Patient characteristics and coexisting illnesses
Patient demographic information was obtained from
health plan electronic databases. Relevant ICD-9 or
CPT codes found in hospital discharge databases dur-
ing the eight years before the procedure date were
used to identify prior cardiovascular disease including
prior myocardial infarction, prior angina, prior PCI or
coronary artery bypass graft (CABG) surgery, history
of ischemic stroke and peripheral arterial disease. Prior
chronic heart failure was determined based on a
validated algorithm using information from hospitaliza-
tion, outpatient and emergency department diagnostic
codes[30].
Relevant data sources were searched for cardiovascu-
lar risk factors. Diabetes mellitus was identified from a
validated longitudinal Diabetes Registry relying on
inpatient and outpatient diabetes diagnoses, receipt of
anti-diabetic therapies, and abnormal glycosylated
hemoglobin or blood glucose levels [31]. Hypertension
was based on serial ambulatory diagnoses or the com-
bination of diagnoses and receipt of anti-hypertensive
medications. Chronic lung disease, systemic malig-
nancy, and history of gastrointestinal bleeding were
determined based on validated methods [29-35]. The
presence and severity of chronic kidney disease was
ascertained using the abbreviated four-variable Modifi-
cation of Diet in Renal Disease (MDRD) equation for
estimated glomerular filtration rate based on most
recent outpatient determination of serum creatinine
within the previous 24 months before the year exam-
ined[33].
Medication usage
Prior observational studies comparing outcomes for DES
and BMS have not included the chronic outpatient use
of cardioprotective medications, an important potential
confounder [6,19,36]. Outpatient medication use within
30 days before PCI was ascertained from health plan
pharmacy records for therapies known to lower cardio-
vascular risk, including beta-blockers [37], angiotensin-
converting enzyme (ACE) inhibitors or angiotensin
receptor blockers (ARBs),[38] statins [39], and thieno-
pyridines [40]. Outpatient warfarin use was also
assessed. More than 90% of patients had a drug benefit
that provided strong financial incentives to obtain medi-
cations from health plan pharmacies.
Primary outcomes
Death from any cause occurring within thirty days and
one year after the procedure was identified from health
plan administrative databases, proxy information, Social
Security Administration vital status files, and California
state death certificate information[41,42]. Subsequent
hospitalized myocardial infarction based on ICD-9-CM
codes (primary discharge diagnosis coded as 410.x1)
within one year was also identified.
Statistical analysis
Three separate methods were used to compare out-
comes after DES and BMS: 1) statistical adjustment
based on propensity score decile, 2) propensity-score
matching, and 3) a stent era comparison, in which out-
comes before and after the introduction of DES in 2003
were compared.
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Because patients were not eligible to receive DES until
after April of 2003, only PCI procedures after this date
were included in the propensity score methods. A non-
parsimonious logistic regression model was used to gen-
erate propensity scores for the likelihood of receiving
DES based on 23 demographic and clinical variables.
Propensity score deciles were created, and logistic
regression was performed modeling the association of
DES with outcomes, adjusted for propensity score decile
(categorical variable) as well as the complete set of
patient covariates. To accommodate data from indivi-
duals who may have undergone multiple procedures
during the study period, robust standard errors account-
ing for clustering by patient were used.
Method 2: propensity-score matching
In the second method, one-to-one nearest neighbor
matching was performed to compare outcomes after
DES and BMS in patients undergoing PCI after April
2003. Caliper width was set at 0.0001 using the STATA
program psmatch2 (Leuven and Sianesi, 2003) [43].
Adequacy of the match was assessed by estimating the
standardized differences between DES and BMS patients
for all variables. Outcomes were compared between
groups using the McNemar’sC h i - s q u a r et e s tf o r
matched comparisons.
Method 3: stent era comparison
Because DES was not available before 2003 and from
2004 onward DES was used in the vast majority of cases,
a comparison of outcomes of PCI prior to and after DES
introduction serves as a useful surrogate for assessing the
impact of DES (Figure 1) [4,36,44]. Procedures between
January 1998 and March 2003 were assigned to the ‘BMS
era’, while those between April 2003 and December 2007
were assigned to the ‘DES era’. This variable would be
expected to be strongly associated with treatment assign-
ment, and less prone to unmeasured confounding by
stent indication. Logistic regression was then performed
to determine the association of stent era with outcomes,
adjusted for all assessed covariates.
Analyses were performed using STATA (Stata Corp.
2008. Stata Statistical Software: Release 10, College Sta-
tion, TX: StataCorp LP). A two-sided P value of < 0.05
was considered significant for all analyses.
Results
A total of 35,438 PCIs with stent placement between
January 1998 and December 2007 were included. Of
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Figure 1 Rates of percutaneous coronary intervention with drug-eluting and bare metal stents between 1998-2007, per 100,000
person-years. All stents prior to April 2003 were bare metal, and 88.3% of stents after April 2003 were drug-eluting.
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utilized BMS. Patients receiving DES were significantly
different than those receiving BMS in nearly all base-
line characteristics, including having significantly
higher rates of hypertensions, diabetes, and congestive
heart failure (Table 1). DES patients also had lower
rates of presentation with ST-elevation myocardial
infarction within 30 days prior to PCI, and were more
likely to be receiving outpatient cardioprotective
medications including statins, beta-blockers and thie-
nopyridines. Crude-mortality was significantly higher
at thirty days (2.2% versus 1.6%, P < .001) and one
year (5.1% versus 4.6%, P = 0.04) after PCI with BMS
compared to DES. The rate of myocardial infarction
at one year was 4.7% after BMS and 4.3% after DES
(P =0 . 0 6 ) .
Patients receiving BMS after April 2003 were mark-
edly different than those receiving BMS before April
2003, having higher rates of hypertension (65.0% versus
46.8%, P < 0.001), congestive heart failure (4.3% versus
3.2%, P = 0.008), prior PCI (9.3% versus 5.6%, P <
0.001), systemic malignancy (9.3% versus 5.2%, P <
0.001) and prior gastrointestinal bleeding requiring hos-
pitalization (3.0% versus 1.7%, P < 0.001). Crude-mortal-
ity at thirty days and one year and myocardial infarction
at one year after PCI were significantly higher in
patients receiving BMS after April 2003 compared those
receiving BMS before 2003 (Figure 2).
Association between stent type and outcomes by
analytical method
After propensity-score adjustment, DES was associated
with significantly lower mortality at thirty days (OR
0.49, 95% CI 0.39 - 0.63, P < 0.001) and one year (OR
0.58, 95% CI 0.49 - 0.68, P < 0.001), as well as a lower
rate of myocardial infarction at one year (OR 0.72, 95%
CI 0.59 - 0.87, P < 0.001). After 1:1 propensity-score
matching (n = 4,126), DES was again associated with
significantly lower mortality at thirty days (OR 0.55, 95%
CI 0.35 - 0.85, P = 0.005), and at one year (OR 0.70,
95% CI 0.52 - 0.92, P = 0.01). Myocardial infarction at
one year was similar (OR 0.94, 95% CI 0.71 - 1.25, P =
0.67). All standardized differences between groups were
< 10%, suggesting an adequate match (Table 2). In the
stent era comparison, no differences in mortality were
seen when comparing the DES era versus BMS era at
thirty days (OR 0.92, 95% CI 0.78 - 1.10, P =0 . 3 9 )o r
one year (0.92, 95% CI 0.82 - 1.02, P = 0.12), or in the
rate of myocardial infarction at one year (OR 0.92, 0.82
- 1.03, P = 0.16) (Figure 3).
Discussion
We have shown that after the introduction of drug-elut-
ing stents, bare metal stents were reserved for patients
with significant comorbidities and high mortality rates.
Commonly used propensity-score methods continued to
suggest a mortality benefit to DES, while a stent era
comparison showed no significant differences in all out-
comes for DES and BMS, similar to results from rando-
mized clinical trials.
Table 1 Characteristics of Patients Undergoing PCI by
Stent Type, 1998-2007
Drug-
Eluting
Stent
Bare
Metal
Stent
P Value
N 19,103 16,335
Age (years) 64.1 63.2 < 0.001
Male Sex (%) 70.8 70.6 0.72
Race/Ethnicity (%) < 0.001
Asian 9.8 7.0
Black 5.3 5.3
Hispanic 9.4 8.4
White, non-Hispanic 65.8 72.1
Other 9.7 7.3
Comorbidities (%)
Diabetes 33.8 26.2 < 0.001
Hypertension 68.5 49.6 < 0.001
Prior MI 13.0 11.1 < 0.001
PCI Indication: < 0.001
STEMI 16.0 27.5
NSTEMI 28.0 19.3
Stable or unstable angina 57.3 54.8
Prior PCI 19.1 14.1 < 0.001
Prior CABG 5.7 5.3 0.12
Congestive Heart Failure 4.6 3.4 < 0.001
Prior Stroke 1.6 1.2 0.005
Peripheral Arterial Disease 4.3 3.3 < 0.001
Glomerular Filtration Rate < 0.001
> 90 15.0 16.2
60 - 89 39.7 33.4
30 - 59 21.5 15.2
15 - 30 1.9 1.3
< 15 or HD 0.7 0.5
Unknown 21.1 33.3
Systemic Malignancy 5.7 5.8 0.75
Prior Gastrointestinal Bleeding 2.3 1.8 < 0.001
Chronic Lung Disease 18.3 21.9 < 0.001
Medications
b-Blockers 50.0 40.1 < 0.001
Clopidogrel 12.7 6.3 < 0.001
Statin 51.7 34.8 < 0.001
ACE-I/ARB 41.9 27.8 < 0.001
Warfarin 3.8 3.0 < 0.001
Abbreviations: MI, myocardial infarction; STEMI, ST-elevation myocardial
infarction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous
coronary intervention; CABG, coronary artery bypass graft surgery.
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Figure 2 Unadjusted outcomes after percutaneous coronary intervention. Outcomes after percutaneous coronary intervention (PCI) with
drug-eluting versus bare metal stents for the overall cohort are shown in A. Outcomes after PCI with bare metal stents before and after April
2003 (B). Patients receiving bare metal stents after April 2003 have significantly worse unadjusted outcomes compared to those receiving bare
metal stents before April 2003.
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DES to BMS have suggested reductions in mortality
and myocardial infarction associated with DES, the
majority of which have utilized propensity-score meth-
ods to mitigate potential confounding [5-20]. However,
data from randomized trials have not corroborated
these findings [21-27]. In a meta-analysis of 22 rando-
mized trials and 34 observational studies, Kirtane et al
found no differences in mortality or myocardial infarc-
tion in randomized trials, but consistent reductions for
both outcomes in observational studies, and attributed
these differences, at least in part, to residual confound-
ing by unmeasured differences between patients receiv-
ing BMS and DES [23]. Our results are consistent with
this conclusion. In our cohort, patients who received
BMS after April 2003 had significantly greater comor-
bidities and unadjusted death and myocardial infarc-
tion rates compared to patients who received BMS
before this date, suggesting that physicians selectively
reserved BMS for a sicker population of patients after
DES was introduced. While propensity-score adjust-
ment and matching both attempt to account for such
differences, they only account for variables that are
assessed. In the presence of such a high degree of
patient selection, any residual confounding in this case
is likely to lead to the appearance of improved out-
comes with DES, as was seen in this study. While pro-
pensity scores have been put forward as a method
which overcomes some of the limitations of traditional
logistic regression, they do not address a primary
threat to the validity of such studies - unmeasured
confounding.
A comparison of the BMS era (100% BMS) to the
DES era (88.3% DES) as a surrogate for a BMS-DES
comparison eliminates the unwanted influence of
patient selection [45]. Consistent with this, the stent
era comparison showed no differences in mortality or
myocardial infarction between BMS and DES, most
closely approximating results seen in randomized trials.
However, because such an analysis compares patients
undergoing PCI at two different times, important secu-
lar trends may have influenced the results. For exam-
ple, comparisons of stent eras in the Medicare
population and in the New York PCI Registry both
suggested lower rates of myocardial infarction in the
DES era compared to BMS era [36,44]. However,
neither study adjusted for differences in the use of out-
patient medications such as statins and beta-blockers,
which have increasingly been used in patients with
coronary disease over time [46]. In this study, we
found significantly higher rates of use of beta blockers,
statins, angiotensin-converting enzyme inhibitors, and
thienopyridines in the DES era. After accounting for
these and other secular trends, no differences in myo-
cardial infarction were observed between DES and
BMS patients.
A number of circumstances specific to stent use
allowed for the critical examination of these analytical
methods. First, the rapid uptake of DES over BMS cre-
ated a natural experiment allowing use of a stent era
comparison. Second, because a large number of patients
from randomized clinical trials comparing DES with
BMS have been performed, these studies help provide
an estimate of the ‘truth.’ However, in other examples in
which the questions of interest may be less well studied,
there could be much greater difficulty interpreting dis-
parate results.
Table 2 Standardized Differences Between BMS and DES
Patients Before and After Matching, April 1, 2003 -
December 31, 2007
Standardized
Difference Prior to
Match
Standardized
Difference Post
Match
N (2,518 BMS, 19,101
DES)
(2,063 BMS, 2,063
DES)
Age (years) -8.3 1.9
Male Sex (%) -1.7 -6.2
Race/Ethnicity -11.3 -5.8
Comorbidities (%)
Diabetes 9.1 3.5
Hypertension 7.5 -3.2
Prior MI 2.7 4.7
PCI Indication: -21.6 0.2
Prior PCI 6.1 6.1
Prior CABG 2.5 2.5
Congestive
Heart Failure
3.8 3.8
Prior Stroke 0.0 0.0
Peripheral
Arterial Disease
1.9 1.9
Glomerular
Filtration Rate
0.3 0.3
Systemic
Malignancy
-13.4 0.4
Prior
Gastrointestinal
Bleeding
-4.2 -0.6
Chronic Lung
Disease
-0.3 7.8
Medications
b-Blockers 11.9 -1.1
Clopidogrel 8.9 3.4
Statin 12.3 5.3
ACE-I/ARB 9.2 4.1
Warfarin 1.0 3.1
Abbreviations: MI, myocardial infarction; PCI, percutaneous coronary
intervention; CABG, coronary artery bypass graft surgery.
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In summary, we have compared outcomes after PCI
with either DES or BMS, using three commonly used
methods of adjustment in observational studies. Large
baseline differences in BMS and DES groups
suggested strong treatment selection, which were
incompletely adjusted for by propensity-score meth-
ods. In the presence of such treatment selection,
alternative methods of analysis of observational data
should be considered.
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Figure 3 Association between stent type and 30-day and 1-year mortality, and myocardial infarction at 1 year using different
analystical methods. Results are for (A) propensity-score adjustment; (B) 1:1 propensity score matching; and (C) a stent era comparison. The
stent era comparison gives results most consistent with findings from randomized clinical trials.
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